Research Analysts Issue Forecasts for CRSP Q3 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Tuesday, February 11th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($0.94) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.09) EPS.

A number of other equities research analysts have also issued reports on CRSP. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $75.56.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $43.30 on Thursday. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of -15.30 and a beta of 1.67. The stock’s 50-day moving average is $42.06 and its 200-day moving average is $46.25. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC boosted its position in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the period. Baker BROS. Advisors LP boosted its holdings in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares during the period. State Street Corp grew its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Norges Bank acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $17,458,000. Finally, Contrarius Group Holdings Ltd acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $14,516,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.